ArticleActa dermato-venereologica2025
Systemic Treatments for Lichen Planopilaris and Frontal Fibrosing Alopecia: A Retrospective Study of 315 Patients.
Article in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Managing the unmanageable? Practical guidance for lichen planopilaris.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Clinical Insights and Prognostic Factors in Frontal Fibrosing Alopecia and Lichen Planopilaris: A Retrospective Cohort Study.Dermatology (Basel, Switzerland) · 2026Article
- Different Patterns of Lichen Planus in Three Members of One Family.Case reports in dermatological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichen planopilaris and frontal fibrosing alopecia are common variants of primary lymphocytic cicatricial alopecia, leading to permanent hair loss. Despite widespread use of various systemic treatments, evidence-based guidelines for these conditions are lacking. This study investigates the effectiveness of systemic treatment options in patients with lichen planopilaris and frontal fibrosing alopecia through a retrospective cohort analysis. Medical records of patients treated at the Department of Dermatology between 2016 and 2022 at the Erasmus University Medical Center Rotterdam, the Netherlands were reviewed. Of 315 patients identified (161 lichen planopilaris and 154 frontal fibrosing alopecia), the majority were female (90.5%), with hydroxychloroquine being the most common systemic treatment, used by 65.2% of lichen planopilaris and 57.8% of frontal fibrosing alopecia patients. Methotrexate had the highest response rate for lichen planopilaris (79.2%), while retinoids showed the highest response for frontal fibrosing alopecia (73.9%). However, treatments with cyclosporine A and retinoids had higher discontinuation rates due to side effects. This study suggests methotrexate and cyclosporine A may be most effective for lichen planopilaris, and cyclosporine A and retinoids for frontal fibrosing alopecia, though side effects remain a concern. Limitations include the retrospective design and the absence of standardized outcomes. Prospective studies are recommended to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.